Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
Product Specifications
CAS Number
1380723-44-3
Product Name Alternative
MPDL3280A; RG-7446; RO-5541267
UNSPSC
12352203
Target
Apoptosis; Autophagy; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Anti-PD-L1_Neutralizing_Antibody.html
Purity
99.9
Solubility
H2O
Smiles
[Atezolizumab]
Molecular Weight
(144.6 kDa)
References & Citations
[1]Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42 (3) :484-7.|[2]Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12 (2) :164. Published 2021 Feb 8.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
